Imcyse

Imcyse is a clinical-stage biopharmaceutical company dedicated to developing novel active and specific immunotherapies for the treatment of severe, chronic autoimmune diseases. The company's unique technology platform has the potential to address a wide range of immunological indications. It is based on the administration of modified synthetic peptides—ImotopesTM—that can specifically block inappropriate immune responses. Imcyse's approach evolves over time, helping to prevent and treat diseases without current alternative therapies, and can cure patients without compromising their immune defenses.